Approach

Summary

Licensing status

Publication and contact information

Drug delivery

Integrin avb3 (CD51/CD61)-targeting nanoparticles for retinal capillary endothelial cell drug delivery

In vitro and mouse studies suggest integrin avb3-targeted nanoparticles could be useful for delivering drugs to retinal capillary endothelial cells to help treat ophthalmic diseases such as age-related macular degeneration (AMD) and diabetic retinopathy. In culture, integrin avb3-targeted quantum dots showed increased binding to human endothelial cells compared with nontargeted controls. Binding was not increased in other cell types. In healthy mice, integrin avb3-targeted quantum dots showed specific and increased accumulation in retinal vascular endothelial cells compared with nontargeted controls. Next steps could include evaluating the use of the targeted nanoparticles for delivering drugs in models for ophthalmic disease.

SciBX 6(15); doi:10.1038/scibx.2013.375
Published online April 18, 2013

Patent and licensing status unavailable

Pollinger, K. et al. Proc. Natl. Acad. Sci. USA; published online March 25, 2013;
doi:10.1073/pnas.1220281110
Contact: Achim Goepferich, University of Regensburg, Regensburg, Germany
e-mail:

achim.goepferich@chemie.uni-regensburg.de